2022
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, De los Santos M, Leon P, Breban MI, Billig K, Yildirim I, Pearson C, Downing R, Gagnon E, Muyombwe A, Razeq J, Campbell M, Ko AI, Omer SB, Grubaugh ND, Vermund SH, Iwasaki A. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nature Medicine 2022, 28: 481-485. PMID: 35051990, PMCID: PMC8938264, DOI: 10.1038/s41591-022-01705-6.Peer-Reviewed Original ResearchConceptsTwo-dose regimenOmicron variantVaccine boosterMRNA vaccinesNeutralization activityDelta variantTwo-dose mRNA vaccinesVirus-specific antibody levelsSARS-CoV-2 Omicron variantMRNA vaccine boosterNeutralization of OmicronNumerous spike mutationsSARS-CoV-2 DeltaPotent neutralization activityInfection-induced immunityCOVID-19 vaccineBNT162b2 boosterBooster vaccinationPrime vaccinationAntibody levelsAntibody titersHumoral immunityImmune escapeInactivated vaccinesVaccine
2018
Surveillance of Maternal Syphilis in China: Pregnancy Outcomes and Determinants of Congenital Syphilis
Zhang X, Yu Y, Yang H, Xu H, Vermund SH, Liu K. Surveillance of Maternal Syphilis in China: Pregnancy Outcomes and Determinants of Congenital Syphilis. Medical Science Monitor 2018, 24: 7727-7735. PMID: 30370903, PMCID: PMC6216479, DOI: 10.12659/msm.910216.Peer-Reviewed Original ResearchConceptsAdverse pregnancy outcomesPregnancy outcomesCongenital syphilisPregnant womenFirst antenatal care visitEligible pregnant womenPrevention of motherAntenatal care visitsIndependent risk factorMultivariable regression analysisLogistic regression analysisRegression analysisChild transmissionMaternal syphilisAntenatal careCare visitsNeonatal asphyxiaNeonatal deathFirst trimesterRisk womenAntibody titersAntenatal testingEpidemiological characteristicsRisk factorsSyphilis diagnosis
1998
Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines
Connor RI, Korber B, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM. Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines. Journal Of Virology 1998, 72: 1552-1576. PMID: 9445059, PMCID: PMC124637, DOI: 10.1128/jvi.72.2.1552-1576.1998.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1Immunodeficiency virus type 1Virus type 1MN rgp120Antibody responseHIV-1Recombinant gp120 subunit vaccinePhase I/II clinical trialsCytotoxic T lymphocyte responsesType 1Immunoglobulin G antibody responseGp120 subunit vaccineSyncytium-inducing (SI) phenotypeT lymphocyte responsesG antibody responseClade B virusesInducing (NSI) phenotypeInfected vaccineesNSI strainsPlacebo recipientsVaccine recipientsViral burdenPlacebo vaccineAntibody titersMultiple immunizations